Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01259323 · ClinicalTrials.gov registry record · Phase 1

Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis

A Phase 1 study of Dermatitis, sponsored by Regeneron Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
10
Study locations

NCT01259323 is a Phase 1 study of Dermatitis that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 30 participants, below the 174-participant average among 6 other Dermatitis trials with a reported enrollment target (83% lower). The trial reports 10 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01259323, a Phase 1 study of Dermatitis, has completed, sponsored by Regeneron Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this study is to assess the Safety and Tolerability of REGN668 (how the body reacts to the drug) compared to placebo (an inert substance) in patients with moderate-to-severe extrinsic Atopic Dermatitis.

Conditions Studied

Dermatitis

Interventions

  • BIOLOGICAL REGN668

Study Locations (10)

California

  • - Los Angeles
  • - Riverside

New York

  • - New York
  • - Rochester

Florida

  • - Miami

Illinois

  • - Chicago

Michigan

  • - Troy

Oregon

  • - Portland

Pennsylvania

  • - Philadelphia

Texas

  • - Dallas

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2010-12
Est. Completion 2012-07
Phase Phase 1

Sponsor

Regeneron Pharmaceuticals

280 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01259323

The ClinicalTrials.gov registry entry for NCT01259323 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 174-participant average among 6 other Dermatitis trials with a reported enrollment target (83% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which REGN668 is the first listed.

NCT01259323 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, New York, Florida.

Frequently Asked Questions

What is clinical trial NCT01259323 about?

NCT01259323 is a clinical study titled "Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis". The purpose of this study is to assess the Safety and Tolerability of REGN668 (how the body reacts to the drug) compared to placebo (an inert substance) in patients with moderate-to-severe extrinsic Atopic Dermatitis.

What is the current status of trial NCT01259323?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2010-12. Estimated completion is 2012-07.

What conditions does trial NCT01259323 study?

This clinical trial studies the following conditions: Dermatitis.

What interventions are being tested in trial NCT01259323?

The interventions under investigation include: REGN668 (BIOLOGICAL).

Who is sponsoring clinical trial NCT01259323?

This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01259323 being conducted?

This trial has 10 study locations across California, Florida, Illinois, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Dermatitis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.